ACT. See Association for Convulsive Therapy (ACT)
ACTH. See adrenocorticotropic hormone (ACTH)
acute-phase ECT, 35
additional treatments, 76, 77
adolescents, 21, 55, 69
adrenocorticotropic hormone (ACTH), 6
advantages, 49, 51, 69
adverse effects, 25, 32, 69, 78, 88, 95, 96
adverse events, 37
affect restricted, 24
affective features, 20
age, 24, 54, 55, 56, 57
age-based dosing, 54, 55
agitation, 20, 28, 49, 69, 96
airway, 70, 71, 72
airway management, 70, 72
airway secretions, 71
alcohol, 24
alfentanil, 68, 69
algorithms, 54, 76
allergies, 23
AMD. See anterograde memory dysfunction (AMD)
amygdala, 4
analgesics, 70
anatomical factors, 52, 58, 66
anesthesia, 3, 9, 10, 22, 23, 24, 26, 33, 34,
35, 50, 55, 61, 67, 69, 71, 72, 74, 96,
101, 102, 103
anesthetic agents, 79
anesthetics, 67, 68
aneurysm, 27
angina, 74
animal studies, 4, 5
ankle, 54, 70, 79, 80, 81
antecubital vein, 79
anterograde memory dysfunction (AMD), 96, 97
antianginals, 36
antiarrhythmics, 30, 36, 73
antiarythmics, 35
antiasthmatics, 35
antiarrhythmics, 29, 30, 71
anticholinergic agent, 71
anticholinergics, 28, 31, 71
anticoagulants, 36
anticonvulsant effect, 7
anticonvulsant theory, 7
anticonvulsants, 6, 7, 24, 29, 34, 35, 55,
68, 69, 74, 76, 77, 78
antidepressants, 1, 2, 3, 5, 6, 7, 9, 31, 32,
35, 55, 56, 69, 90, 95
antihypertensive agents, 29, 61, 73
antihypertensives, 29, 30, 36, 73, 75
antipsychotic effects, 5, 20, 34
antipsychotics, 31, 34
anxiety, 24, 33, 67
APA Task Force on Electroconvulsive Therapy, 3
apnea, 36, 68
appropriate dose, 56
arousal, 10
arrhythmias, 30, 73, 74
artifact, 58, 62, 66, 67
aspiration, 31, 72
assessment, 23, 25, 67, 89, 101
Association for Convulsive Therapy (ACT), 2
asthma, 27, 30, 73
asystole, 10
Ativan, 78
atropine, 30, 71
auditory meatus, 51
augmentation, 69
autism, 21, 106
availability, 3, 5, 30
awakening, 31, 96
barbiturates, 68
basal ganglia, 4
basics of the treatment, 1
Beck Depression Inventory, 25
benefits, 21, 23, 26, 28, 105
### Index

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>110</td>
<td>benzodiazepine, 33, 34, 35, 77, 78, 96, 97</td>
</tr>
<tr>
<td></td>
<td>beta-blockers, 29, 30, 73</td>
</tr>
<tr>
<td></td>
<td>bifrontal ECT, 51</td>
</tr>
<tr>
<td></td>
<td>bifrontal electrode placement, 53</td>
</tr>
<tr>
<td></td>
<td>bilateral ECT, 20, 49, 50, 51, 52, 59, 88, 96, 97</td>
</tr>
<tr>
<td></td>
<td>bilateral electrode placement, 50, 51, 53, 57, 90</td>
</tr>
<tr>
<td></td>
<td>bipolar patients, 4, 19, 20, 28, 87, 88</td>
</tr>
<tr>
<td></td>
<td>bite block, 54, 71, 72, 76, 77, 80, 81, 101</td>
</tr>
<tr>
<td></td>
<td>bleeding, 27, 29</td>
</tr>
<tr>
<td></td>
<td>blood flow, 10, 28</td>
</tr>
<tr>
<td></td>
<td>blood oxygen saturation, 61</td>
</tr>
<tr>
<td></td>
<td>blood pressure, 10, 29, 59, 61, 62, 70, 71, 73, 74, 79, 80, 81, 102</td>
</tr>
<tr>
<td></td>
<td>blood volume, 10</td>
</tr>
<tr>
<td></td>
<td>blood–brain barrier, 5, 10, 32, 71</td>
</tr>
<tr>
<td></td>
<td>bolus, 68, 70, 73, 74, 78</td>
</tr>
<tr>
<td></td>
<td>bradyarrhythmia, 30</td>
</tr>
<tr>
<td></td>
<td>bradycardia, 10, 30, 71</td>
</tr>
<tr>
<td></td>
<td>brain, 3, 4, 5, 7, 8, 9, 10, 24, 26, 28, 32, 71, 78</td>
</tr>
<tr>
<td></td>
<td>brain disease, 26, 78</td>
</tr>
<tr>
<td></td>
<td>brain electrical activity, 26</td>
</tr>
<tr>
<td></td>
<td>brain herniation, 28</td>
</tr>
<tr>
<td></td>
<td>brain tumor, 28, 29</td>
</tr>
<tr>
<td></td>
<td>breathing, 62, 102</td>
</tr>
<tr>
<td></td>
<td>brief pulse stimuli, 7, 56</td>
</tr>
<tr>
<td></td>
<td>bronchodilators, 30, 36</td>
</tr>
<tr>
<td></td>
<td>burns, 68, 71</td>
</tr>
<tr>
<td></td>
<td>caffeine, 77</td>
</tr>
<tr>
<td></td>
<td>calcium channel blockers, 73, 74</td>
</tr>
<tr>
<td></td>
<td>calves, 80</td>
</tr>
<tr>
<td></td>
<td>cancer, 95</td>
</tr>
<tr>
<td></td>
<td>canthus, 51, 52</td>
</tr>
<tr>
<td></td>
<td>carbamazepine, 77</td>
</tr>
<tr>
<td></td>
<td>Cardene, 74</td>
</tr>
<tr>
<td></td>
<td>cardiac arrhythmia, 27, 69</td>
</tr>
<tr>
<td></td>
<td>cardiac disease, 29</td>
</tr>
<tr>
<td></td>
<td>cardiac enzymes, 10</td>
</tr>
<tr>
<td></td>
<td>cardiac function, 27</td>
</tr>
<tr>
<td></td>
<td>cardiac repolarization, 10</td>
</tr>
<tr>
<td></td>
<td>cardiovascular agents, 73, 74</td>
</tr>
<tr>
<td></td>
<td>cardiovascular agents, 30, 73</td>
</tr>
<tr>
<td></td>
<td>cardiovascular depression, 68</td>
</tr>
<tr>
<td></td>
<td>cardiovascular disease, 29</td>
</tr>
<tr>
<td></td>
<td>cardiovascular medications, 30, 35</td>
</tr>
<tr>
<td></td>
<td>cardiovascular system, 9, 10, 32, 61, 68, 73, 77, 78, 79</td>
</tr>
<tr>
<td></td>
<td>Cardizem, 74</td>
</tr>
<tr>
<td></td>
<td>carotid artery, 58</td>
</tr>
<tr>
<td></td>
<td>Carroll Rating Scale for Depression, 25</td>
</tr>
<tr>
<td></td>
<td>catatonia, 2, 19, 20, 21, 49, 50, 88, 95</td>
</tr>
<tr>
<td></td>
<td>central nervous system, 9, 27</td>
</tr>
<tr>
<td></td>
<td>cerebral neurons, 9</td>
</tr>
<tr>
<td></td>
<td>cerebrospinal fluid, 5, 7</td>
</tr>
<tr>
<td></td>
<td>charge, 7, 8, 52, 54, 55, 77, 101</td>
</tr>
<tr>
<td></td>
<td>chemotherapy, 96</td>
</tr>
<tr>
<td></td>
<td>childhood, 24</td>
</tr>
<tr>
<td></td>
<td>children, 21, 69</td>
</tr>
<tr>
<td></td>
<td>chin, 72, 80</td>
</tr>
<tr>
<td></td>
<td>cholinesterase inhibitor, 36</td>
</tr>
<tr>
<td></td>
<td>chronic obstructive pulmonary disease, 27</td>
</tr>
<tr>
<td></td>
<td>cigarettes, 24</td>
</tr>
<tr>
<td></td>
<td>cisatracurium, 70</td>
</tr>
<tr>
<td></td>
<td>classical monoamine depletion theory, 5</td>
</tr>
<tr>
<td></td>
<td>clinical monitoring, 88</td>
</tr>
<tr>
<td></td>
<td>chronic motor phase, 9</td>
</tr>
<tr>
<td></td>
<td>cognitive assessments, 25</td>
</tr>
<tr>
<td></td>
<td>cognitive dysfunction, 89</td>
</tr>
<tr>
<td></td>
<td>cognitive effects, 4, 5, 6, 9, 25, 37, 51, 55, 56, 57, 87, 95, 106</td>
</tr>
<tr>
<td></td>
<td>cognitive functioning, 25, 28, 89</td>
</tr>
<tr>
<td></td>
<td>cognitive impairment, 7, 25, 50, 51, 53, 56, 75, 78, 88, 90</td>
</tr>
<tr>
<td></td>
<td>cognitive risks, 23</td>
</tr>
<tr>
<td></td>
<td>combination therapy, 20</td>
</tr>
<tr>
<td></td>
<td>comfort, 1, 67</td>
</tr>
<tr>
<td></td>
<td>comorbidities, 95</td>
</tr>
<tr>
<td></td>
<td>complete blood count, 26</td>
</tr>
<tr>
<td></td>
<td>complications, 22, 29, 37, 50, 77, 87, 95, 103</td>
</tr>
<tr>
<td></td>
<td>concurrent medications, 31</td>
</tr>
<tr>
<td></td>
<td>conduction, 61, 71, 73</td>
</tr>
<tr>
<td></td>
<td>confusion, 50, 68, 96</td>
</tr>
<tr>
<td></td>
<td>connection, 61</td>
</tr>
<tr>
<td></td>
<td>connectivity theory, 7</td>
</tr>
<tr>
<td></td>
<td>Consortium for Research in Electroconvulsive Therapy (CORE), 51, 89</td>
</tr>
<tr>
<td></td>
<td>constant-current, 8, 54</td>
</tr>
<tr>
<td></td>
<td>consultation, 1, 21, 22, 23, 24, 26, 29, 31, 37, 103</td>
</tr>
<tr>
<td></td>
<td>consultation note, 21, 23</td>
</tr>
<tr>
<td></td>
<td>continuation, 20, 35, 89, 90, 91</td>
</tr>
<tr>
<td></td>
<td>continuation treatment, 2, 6, 21, 25, 35, 37, 78, 89, 90, 91, 97, 103, 106</td>
</tr>
<tr>
<td></td>
<td>controversy, 3, 49, 62, 74</td>
</tr>
</tbody>
</table>
CORE. See Consortium for Research in Electroconvulsive Therapy (CORE)
coronary artery disease, 27
cortical structures, 4, 6
crying, 24
CT, 24, 26
cuff technique, 70
cuffed-limb method, 31
current density, 5, 9
current flow, 61
d’Elia placement, 52, 53
DBS. See deep brain stimulation (DBS)
death, 35, 95
deep brain stimulation (DBS), 21
delivery, 8, 9, 33, 54, 59, 60, 61, 71, 72, 75, 76, 81, 105
delta activity, 9
dementia, 28, 50, 89
dentate gyrus, 4
depolarizing agent, 70
depressive symptoms, 19, 22, 24, 25, 32, 89, 91, 95, 96
deterioration, 89
dexamethasone suppression test (DST), 6
dexametadomidine, 97
diabetes, 6, 35
diagnostic psychiatric interview, 21
diaphragm, 70
digoxin, 36
Dilantin, 77
Diltiazem, 74
disadvantages, 49
discomfort, 34, 67, 68
disorientation, 96
distress, 22
diuretics, 35, 36, 73
dopamine, 5, 6, 28
dopaminergic tissue transplantation, 21
dorsum, 58, 66, 67, 79
dose titration, 53, 54, 55, 57, 71, 75
dose titration procedure, 57, 71, 75
dose titration sequence, 54, 55
dosing estimates, 54, 56
dosing strategies, 57, 97
dosing tables, 56
driving, 3, 23, 25
drugs, 5, 6, 24, 31, 34, 70, 73, 74, 102, 106
DST. See dexamethasone suppression test (DST)
duration, 4, 7, 22, 28, 33, 54, 56, 68, 69, 70, 73, 74, 81
dyskinesias, 28
dysrhythmias, 10
ear, 58
ECG, 10, 26, 60, 61, 62, 66, 79, 91, 102
echothiophate, 36
ECS. See electroconvulsive shock (ECS)
ECT
cerebral physiology of, 9
Consultation, 21, 23
course, 9, 24, 33, 56, 73, 76, 89, 96, 97, 103
device, 7, 8, 37, 54, 55, 56, 57, 58, 59, 60, 61, 62, 76, 77, 78, 79, 80, 102
as a First-Line Treatment, 20
ECT Treatment Course, 87
ECT–drug interactions, 28
ectopic beats, 10
Ect-Responsive Illness, 21
education, 23, 101
EEG, 4, 9, 24, 26, 54, 57, 58, 60, 61, 62, 64, 65, 66, 75, 78, 79, 81, 103
EEE Recording Electrodes, 57
EFFECT. See European Forum for ECT (EFFECT)
efficacy, 1, 3, 5, 7, 9, 20, 21, 23, 28, 31, 33, 34, 35, 51, 56, 57
elderly, 20, 28, 55, 68, 76, 77, 96
electrical circuit, 8, 61
electrical dose-titration, 2
electrical safety, 8
electricity, 7
basics of, 7
electroconvulsive shock (ECS), 4, 5, 6, 7
Electroconvulsive Therapy
basic concepts of, 1
electrode edge, 52
electrode paddles, 59
electrode placement, 5, 9, 21, 22, 23, 25, 28, 49, 50, 51, 52, 55, 56, 57, 58, 62, 89, 90, 96, 103, 106
electrode site preparation, 57
electrode sites, 8, 51, 52, 79
electrolytes, 26, 91
emergencies, 3, 37
EMG, 58, 60, 61, 66, 79
EMG electrodes, 58, 79
EMG Recording Electrodes, 58
EMG tracing, 66
endorphins, 6
energy, 7, 8, 54, 55, 88
environment, 2, 81, 96, 102
epilepsy, 7, 29, 34
escitalopram, 24
esmolol, 29, 61, 73, 74, 75
Etomidate, 68, 69
European Forum for ECT (EFFECT), 2
euthymesin, 6
eye, 36, 51, 52
eyebrow, 58
family, 3, 22, 36, 37, 88, 91, 98, 102, 105
fasciculations, 70, 80, 98
FDA, 25
fever, 33
first treatment, 50, 57, 67, 70, 71, 74, 75, 96, 98
fixed high charge, 56
fixed high-dose therapy, 54, 56
flumazenil, 34
fluphenazine, 34
foot, 58, 59, 66, 67, 70
forearm, 70, 79
forehead, 9, 51, 52, 58, 62
frequency of treatments, 90
frontal leads, 58
frontotemporal, 58, 62, 66
frontotemporal electrode, 59
GABA, 6, 7, 34
gastroesophageal reflux, 36, 72
gastroesophageal reflux disease (GERD), 36
gastrointestinal disorders, 31, 36
gauze pad, 59
gel, 59, 61
GERD. See gastroesophageal reflux disease (GERD)
glaucoma, 36
glutamate, 6
glycopyrrolate, 30, 71
gooseflesh, 10
gray matter, 4
guidelines, 35, 50, 57
H1 blocker, 36, 72
hairline, 58
hallucinations, 68
haloperidol, 34
Hamilton Rating Scale for Depression (HRSD), 25, 50, 88
handedness, 23
handheld electrode, 59
headache, 55, 98
headband, 59
heart, 10, 22, 62, 69, 71, 73, 74
heart rate, 10, 62, 71, 73, 74
hemispheres, 58, 70
hemodynamic responses, 69
hepatotoxicity, 33
heritability, 22
high impedance, 61
high stimulus doses, 56
hippocampus, 4, 6
history, 20, 21, 22, 23, 25, 26, 29, 31, 35, 71, 74, 77, 89, 90, 105, 106
hobbies, 24
hormones, 6
hospital ECT, 21
hospitalization, 3, 90
hospitals, 2, 3, 21, 23, 37, 88, 90, 102, 103
HPA. See hypothalamic-pituitary-adrenal (HPA)
HRSD. See Hamilton Rating Scale for Depression (HRSD)
hydralazine, 73, 74
hyperreflexia, 33
hypersynchronous polyspikes, 9
hypertension, 10, 27, 29, 30, 33, 55, 68, 69, 73, 74, 77
hyperventilation, 71, 76, 77
hypnotic dose, 68, 69
hypoglycemics, 35
hypomania, 24, 87
hypotension, 29, 33, 35, 73, 74
hypothalamic-pituitary-adrenal (HPA), 6
imipramine, 33
impedance, 8, 54, 61, 76, 77, 80, 81
improvement, 20, 87, 89
incontinence, 35
indications, 19, 20, 34, 103, 106
individualization, 90
induction agent, 67, 69, 72, 74, 79, 80, 97
informed consent, 21, 23, 25, 36, 37, 79
initial stimuli, 57
insight, 24
insurances, 3
intensity, 4, 33, 52, 76
interelectrode distance, 62
International Society for ECT and Neurostimulation (ISEN), 2
intervention, 10, 75
intracerebral hemorrhage, 27
intracranial pressure, 10, 26, 27, 28
intubation, 30, 72
involuntary ECT; 37
irritant, 68
ischemia, 11, 73, 77
ISEN. See International Society for ECT and Neurostimulation (ISEN)
Isoptin, 74
jaw, 72
joules, 8, 54
judgment, 1, 24, 74, 90
ketamine, 22, 68, 69
ketoadicosis, 35
ketorolac, 98
labetalol, 29, 61, 73, 74, 75
laboratory evaluation, 23, 25, 26
language function, 50
laterality, 50, 56
left hemisphere, 50, 62
left-handedness, 50
leg, 67, 70
length of ECT course, 88
lesions, 10, 26, 27, 28
lidocaine, 3, 35, 36, 74, 77
limitations, 23
lips, 72
lithium, 20, 26, 32, 35, 90
liver, 26
location of electrodes, 51
long seizures, 75
lorazepam, 33, 78
low impedance, 61
lung, 22
maintenance, 35, 89, 91
maintenance treatment, 2, 20, 21, 28, 35, 37, 89, 90, 91, 97, 106
major depression, 19, 27
major depressive episode, 19
major psychiatric illnesses, 3
malnutrition, 20
mania, 19, 20, 49, 87
mania, delirious, 20
mania, severe, 20, 49
manic episode, 20
MAOI, 25, 33
mastoid bone, 58
mastoid process, 58
mechanism of action, 3, 4, 6, 7
MECTA, 56, 58, 66, 80
MECTA devices, 56
medical condition, 26, 27, 30, 50, 55
medical factors, 25
medical issues, 23, 103
medical physiology, 9
medical problems, 21, 22
medical risks, 23
medical status, 23, 26, 91
Medicare, 3
medication, 20, 21, 22, 24, 29, 30, 31, 32, 36, 55, 61, 72, 73, 74, 78, 79, 89, 90, 106
medication management, 25
medication – ECT strategies, 35
medications, 1, 2, 3, 5, 23, 24, 29, 30, 31, 32, 34, 35, 36, 74, 79, 89, 90, 91, 101, 103
memory dysfunction, 25
memory function, 88, 95, 97
memory loss, 95, 96, 97, 98, 105
meningiomas, 28
mental status examination, 25, 26
metabolic panel, 26
metabolism, 10
metal electrodes, 59
metal stimulus electrodes, 59
methohexital, 68, 69, 74, 78, 79
metoclopramide, 31, 36
midazolam, 34, 78, 97
Mini-Mental State Exam (MMSE), 25, 89
missed seizures, 75
mivacurium, 70
mixed affective state, 19
MMSE. See Mini-Mental State Exam (MMSE)
MoCA, 25, 89
modifications, 9, 21, 22, 27, 28, 77
monitoring, 30, 57, 58, 61, 62, 66, 88, 91, 103
monoamine systems, 5
Montgomery-Asberg Depression Rating Scale, 25, 89
Montreal Cognitive Assessment (MoCA), 25, 89
mood, 2, 6, 20, 21, 22, 24, 35, 88, 89, 90, 95
mood disorders, 2, 6, 22, 89, 95
motivation, 24
motor systems, 28
mouth, 72, 73, 80, 90
MRI, 4, 5, 24, 26
MRS, 4
Muscle Aches, 98
muscle relaxant, 66, 67, 70, 80, 98
muscle relaxant effect, 66
muscle relaxation, 31
muscles, 66, 72, 98
muscular relaxation, 67, 70
assessment of, 70
musculoskeletal disorders, 31
musculoskeletal injury, 70
myalgias, 98
myocardial infarction, 27, 29, 74
myocardial ischemia, 10, 29, 71, 73, 74
myoclonic jerks, 69
myoclonus, 68

— 69

National Institute of Mental Health (NIMH), 2
nausea, 55, 98
near-threshold dosing, 56
neostigmine, 71
nerve stimulator, 59, 61, 66, 70, 80, 102
neural networks, 7
neurobiology, 3
neuroendocrine theory, 6
neurogenesis, 4
neurohormones, 7
neurohumoral substances, 6
neuroleptic malignant syndrome (NMS), 20, 21, 31
neuroleptics, 31
neurological aspects, 9
neuromuscular junction, 70
neuropeptide, 6
neurophysiologic effects, 10
neuropsychological assessment, 25
neurotransmission, 5, 6
neurotransmitters, 6
neurotrophic effects, 4
neurotrophic theory, 4
nicardipine, 74
nicardipine, 74
NIMH. See National Institute of Mental Health (NIMH)
nitrites, 29, 35, 74

nitroglycerin, 30, 73, 74
NMDA antagonist, 69
NMS. See neuroleptic malignant syndrome (NMS)
nondepolarizing muscle relaxants, 70
nortriptyline, 90
nothing by mouth, 72
nothing by mouth status (NPO), 3, 23, 25, 72, 79
NPO. See nothing by mouth status (NPO)
number of treatments, 22, 87, 90
nutritional status, 49

OCD, 24
olanzapine, 97
older patients, 57, 67
ondansetron, 99
opiates, 98
opioids, 7
osteoporosis, 27, 31, 70
outcomes, 4, 25, 98
outpatient ECT, 3, 25, 102
oversleeping, 24
oxygen demand, 10, 73, 74
oxygen saturation, 62
oxygenation, 29, 71

do pallidotomy, 21
paralysis, 70, 71
Parkinson's disease, 20, 27, 106
patient care, 3, 101, 102, 103
patient characteristics, 54, 56
patient selection, 19
patterns, 9, 66
PCP. See phencyclidine (PCP)
peptic ulcer disease, 36
perspiration, 61
PET, 5
pharmacological interventions, 78
pharmacotherapy, 19, 90
phencyclidine (PCP), 69
phenytoin, 77
pheochromocytoma, 27
physical examination, 25, 26
physiological effects, 9
physiological monitoring, 61
piloerection, 10
placement, 49, 50, 51, 58, 60, 61, 67
poor electrical connections, 76
Index

115

post-ECT, 28, 34, 62, 73, 74, 96
postictal agitation, 96, 97
postictal confusional state, 96
postsynaptic effects, 6
pre-ECT evaluation, 25, 26, 103
pregnancy, 20, 30, 72
premedication, 28, 30, 71, 79
pre-procedural evaluations, 23, 25
pretreatment, 34, 61, 70, 72, 98
PRIDE study, 90
prior treatment, 22
proconvulsant, 68, 69, 78
prolactin, 6
propofol, 68, 69, 74, 78, 79, 97
proton pump inhibitor, 36, 72
psychiatric history, 22, 25, 26
Psychiatry Consultation-Liaison service, 21
psychosis, 20, 49
psychotherapy, 22, 24, 89, 91
psychotic symptoms, 22, 24, 32, 34, 69, 88, 95
psychotropics, 31, 32, 35
public, 2, 102
pulmonary aspiration, 30
pulmonary disease, 30
pulse, 56, 61, 102
pulse oximetry, 61
pulse width, 7, 52, 54, 56, 89
QIDS-SR. See Quick Inventory of Depressive Symptomatology-Self report (QIDS-SR)
Quick Inventory of Depressive Symptomatology-Self report (QIDS-SR), 25
rapid and sustained response, 56
rating scales, 88
receptors, 5
recommendation for ECT, 22
recommendations, 3, 23, 57, 74, 103
recovery, 33, 50, 62, 68, 81, 87, 88, 96, 97, 98, 99, 101, 102, 103
referring doctor, 25
reflexes, 67, 70
reflux, 31, 36, 72, 79
relapse prevention, 32
relapse rates, 89, 90
relapses, 35
remifentanil, 68, 69
remission, 19, 32, 89, 90
renal failure, 27
reserpine, 35, 73
resistance, 8, 89
respiration, 71, 97
response, 1, 4, 9, 19, 20, 22, 25, 29, 50, 56, 67, 68, 69, 73, 80, 90, 103
response rate, 19
restimulation, 75
restlessness, 96
retinal detachment, 27
retrograde memory dysfunction (RMD), 96, 97
reversal agents, 71
rhythms, 9
right unilateral ECT, 50, 53, 88, 96
right unilateral electrode placement, 56, 57
risk, 8, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 49, 71, 73, 74, 78, 91, 95, 106
risk–benefit ratio, 91, 95
risks, 21, 22, 23, 25, 26, 28, 29, 30, 50, 74, 91, 95, 96
rituals, 22
RMD. See retrograde memory dysfunction (RMD)
rocuronium, 70
rTMS, 22
safety, 23, 31, 33, 35, 55, 67, 95, 106
saline, 59
scopolamine, 8, 9, 57, 59
Schizoaffective disorder, 19
schizophrenia, 7, 19, 20, 34, 88
seizure, 2, 3, 4, 4, 5, 5, 6, 7, 8, 9, 10, 28, 29, 30, 32, 33, 34, 35, 52, 54, 55, 56, 57, 58, 62, 64, 65, 66, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 81, 97, 98, 103
seizure duration, 4, 78
seizure generalization, 9, 70
seizure induction, 9
Seizure initiation, 63
seizure length, 71, 75, 77
seizure progression, 9
seizure threshold, 2, 7, 8, 29, 33, 34, 52, 54, 55, 56, 57, 75, 76, 77, 78
selegiline, 33
self-adhesive electrodes, 58
self-injury, 2, 21
self-rating scale, 25
self-test, 8, 57, 61
self-test features, 8
sensors, 58
serotonin, 5, 32
sertraline, 24
serum, 58
serious illness, 57, 58, 59, 76
severity criteria, 50
severity of illness, 50
sex, 54, 56
short seizures, 75, 77, 78
side effects, 25, 37, 49, 51, 55, 74, 88
Sinemet, 28
single treatments, 90
site preparation, 57, 58, 59, 76
sites, 58, 59, 62, 66, 76, 79
skin, 57, 59, 60, 61, 70
skin-to-electrode contact, 61
skull, 8, 52
SNRIs, 32
sodium citrate, 31
spasticity, 71
square-wave pulses, 7
SSRIs, 24, 32
ST segment, 10
status epilepticus, 7, 29, 30, 78
Stick-on Electrodes, 57
stimulus cable, 61
stimulus characteristics, 52, 54
stimulus charge, 56
stimulus delivery, 57, 61, 72
stimulus dose, 30, 50, 54, 55, 57, 75, 76, 77, 79, 89
choosing, 57
stimulus dose titration, 30, 54, 75, 76
stimulus dosing, 33, 52, 55, 56, 75, 76, 96
stimulus duration, 7, 77
stimulus electrodes, 9, 59, 60, 61, 76, 79, 80
stimulus site preparation, 58
stimulus, strength of, 52
structural abnormalities, 4
subconvulsive stimuli, 30, 71
subgenual cortex, 4
subsequent treatments, 55, 57, 70, 71, 75, 78, 98
successive treatments, 75
succinylcholine, 31, 36, 61, 66, 67, 70, 71, 72, 80, 98
sugammadex, 71
suicidal intentions, 19, 22, 24, 37, 50
suicidality, 20
suprathreshold stimuli, 55
surge, 10, 29
surgery, 2, 33, 96, 102
sympathetic activation, 10
sympathetic nervous system, 10
symptom severity, 19, 25
symptomatic relief, 19
symptoms, 20, 22, 24, 25, 34, 35, 39, 69, 88, 91
T waves, 10
tachyarrhythmias, 30
tachycardia, 10, 29, 30, 68, 69, 73, 74
TCAs, 32
teeth, 23, 31, 72, 80
temporomandibular joint disease, 31
testing, 22, 25
theophylline, 26, 30, 35, 36, 78
therapeutic effects, 3, 6, 50
thiopental, 68
thought process, 24
thrombin inhibitors, 36
Thymatron devices, 55, 56, 58, 66, 80
thyroid-stimulating hormone (TSH), 6
tibial nerve, 67
time interval between treatments, 57
tissues, 8
toes, 66, 70, 80
tolerability, 21, 22, 23, 95, 106
tone, 10, 34, 67, 70
tracing, 62, 63, 66, 79
transsthoracic echocardiography, 11
trauma, 71
treatment course, 20, 25, 33, 37, 69, 75, 87, 89
treatment frequency, 28, 88, 89
treatment modalities, 22
treatment options, 19, 96
treatment plan, 91
treatment procedure, 62, 79
treatment response, 22
treatment scheduling, 87, 88
treatment session, 67, 76, 97
<table>
<thead>
<tr>
<th>Index</th>
<th>117</th>
</tr>
</thead>
<tbody>
<tr>
<td>treatment trials, 22</td>
<td>variability, 8, 97</td>
</tr>
<tr>
<td>triptans, 98</td>
<td>vecuronium, 70</td>
</tr>
<tr>
<td>TSH. See thyroid-stimulating hormone (TSH)</td>
<td>vegetative signs, 22</td>
</tr>
<tr>
<td>tumors, 28</td>
<td>ventilation, 71, 72, 80, 81, 98</td>
</tr>
<tr>
<td>ultra-brief pulse, 7</td>
<td>ventricular contractions, 30</td>
</tr>
<tr>
<td>ultrabrief pulse stimuli, 2, 54, 56, 57</td>
<td>ventricular dysfunction, 11</td>
</tr>
<tr>
<td>unconsciousness, 68, 71</td>
<td>verapamil, 74</td>
</tr>
<tr>
<td>unilateral ECT, 3, 4, 9, 20, 23, 25, 28, 33, 49, 50, 52, 53, 55, 57, 58, 59, 60, 62, 70, 88, 96, 97, 106</td>
<td>Versed, 78</td>
</tr>
<tr>
<td>unilateral electrode placement, 49, 50, 55</td>
<td>vertex, 52, 59, 60</td>
</tr>
<tr>
<td>unipolar patients, 4, 19, 88, 89</td>
<td>vital signs, 61, 79, 81, 101, 103</td>
</tr>
<tr>
<td>urgency, 19, 22, 49, 55</td>
<td>voltage, 8, 9</td>
</tr>
<tr>
<td>vagal bradyarrhythmias, 71</td>
<td>weight loss, 22</td>
</tr>
<tr>
<td>vagal tone, 10</td>
<td>young adults, 21, 55</td>
</tr>
<tr>
<td></td>
<td>young patients, 55, 57, 70, 78</td>
</tr>
<tr>
<td></td>
<td>Zofran, 99</td>
</tr>
</tbody>
</table>